A phase I/II first-in-human trial of oral SRA737 (a Chk1 inhibitor) given in combination with low-dose gemcitabine in subjects with advanced cancer.
Udai Banerji(Institute of Cancer Research), Robert H. Jones(Clinical Research Institute), Daniel Castellano(Research Institute Hospital 12 de Octubre), Harriet S. Walter(Leicester Royal Infirmary), Alejandro Navarro(Vall d'Hebron Hospital Universitari), Joo Ern Ang(Royal Marsden NHS Foundation Trust), Louise Carter(The Christie NHS Foundation Trust), Elizabeth Ruth Plummer, Patricia Roxburgh(Beatson West of Scotland Cancer Centre), Yvette Drew(Newcastle University), Sarah P. Blagden(Churchill Hospital), Desamparados Roda(Institute of Cancer Research), Ines Verdon(Sierra Wireless (Canada)), Alan Anthoney(St James's University Hospital), Rebecca Kristeleit(King's College London), Debashis Sarker(King's College - North Carolina), Tatiana Hernández(Hospital Universitario Fundación Jiménez Díaz), Víctor Moreno, Amy Quinton(Velindre Cancer Centre), Hendrik‐Tobias Arkenau(Sarah Cannon Research Institute)
Cited by 20
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k